Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of trifarotene cream in lamellar ichthyosis
2018-003272-12Phase 2Unknown
- Sponsor
- Mayne Pharma
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trifarotene in lamellar ichthyosis (LI) (4 arms), sponsored by Mayne Pharma. Primary endpoint: Successful resolution of lamellar ichthyosis at Week 12. Status: unknown.
02
Drugs
trifarotene
03
Conditions
lamellar ichthyosis (LI)
Beyond the preview
Go deeper on 2018-003272-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003272-12.